Back to mobile site

Recent Alzheimer's disease dynamics are a positive for Biogen's Leqembi - analyst

March 11, 2024 2:01 PM EDT Send to a Friend
On Monday, Oppenheimer reiterated its Outperform rating and $290 price target for Biogen (NASDAQ: BIIB) amid recent developments in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login